Time filter

Source Type

Xavier Bosch F.,Catalan Institute of Oncology Institute Catala dOncologia ICO | de Sanjose S.,Catalan Institute of Oncology Institute Catala dOncologia ICO | de Sanjose S.,CIBER ISCIII | Castellsague X.,Catalan Institute of Oncology Institute Catala dOncologia ICO | Castellsague X.,CIBER ISCIII
Cancer Discovery | Year: 2011

Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25. © 2011 American Association for Cancer Research.

Loading Catalan Institute of Oncology Institute Catala dOncologia ICO collaborators
Loading Catalan Institute of Oncology Institute Catala dOncologia ICO collaborators